natgillin/translations-raw huggingface dataset:
Tasigna must not be used in people who are hypersensitive (allergic) to nilotinib or any of the other ingredients.
Zdravila Tasigna ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) nilotinib ali katero koli drugo sestavino zdravila.
Tasigna should be used with caution in patients who have or who are at significant risk of developing prolongation of QTc, such as those: with congenital long QT prolongation
Zdravilo Tasigna je treba uporabljati previdno pri bolnikih, pri katerih je podaljšanje intervala QTc že prisotno oziroma obstaja pomembno tveganje, da do njega pride, kot so bolniki: s prirojeno dolgim intervalom QT,
Tasigna should not be used during breast-feeding.
Zdravila Tasigna se med dojenjem ne sme uporabljati.
Tasigna with food and drink
Zdravilo Tasigna skupaj s hrano in pijačo
Tasimelteon and its most abundant metabolites have no appreciable affinity for more than 160 other pharmacologically relevant receptors.
Tasimelteon in njegovi količinsko najpomembnejši presnovki nimajo občutnejše afinitete do več kot 160 ostalih farmakološko pomembnih receptorjev.
Tasimelteon exposure decreased by approximately 40% in smokers, compared to non-smokers (see section 4.5).
Izpostavljenost tasimelteonu se je pri kadilcih zmanjšala za približno 40 % v primerjavi z nekadilci (glejte poglavje 4.5).
Tasmar 100 mg (only applicable for the outer packaging
Tasmar 100 mg (le na zunanji ovojnini)
Tasmar has also been studied in a ‘switch’ study in 150 patients.
Zdravilo Tasmar so proučevali tudi v študiji „prehoda“ pri 150 bolnikih.
Tasmar has an effect on the symptoms of your Parkinson’s disease.
Zdravilo Tasmar ima učinek na simptome vaše Parkinsonove bolezni.
Tasmar is a pale to light yellow, oval shaped, film-coated tablet.
Zdravilo Tasmar je svetla do rahlo rumena, ovalna, filmsko obložena tableta.
Tasmar is an orange yellow to brown yellow, oval shaped, film-coated tablet.
Zdravilo Tasmar je svetla do rahlo rumena, ovalna, filmsko obložena tableta.
Tasmar is contraindicated for patients with liver disease or increased liver enzymes.
Zdravilo Tasmar je kontraindicirano pri bolnikih z boleznijo jeter ali povišano raven jetrnih encimov.
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-o-methyltransferase (COMT) inhibitors (see section 5.1).
Zdravilo Tasmar se uporablja v kombinaciji z levodopo/benserazidom ali levodopo/karbidopo pri bolnikih z na levodopo odzivno idiopatsko Parkinsonovo boleznijo in motoričnimi fluktuacijami, ki se niso odzvali na ostale zaviralce katehol-O-metiltransferaze (COMT), ali pa jih ne prenašajo (glejte poglavje 5.1).
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase COMT inhibitors (see section 5.1).
Zdravilo Tasmar se uporablja v kombinaciji z levodopo/benserazidom ali levodopo/karbidopo pri bolnikih z na levodopo odzivno idiopatsko Parkinsonovo boleznijo in motoričnimi fluktuacijami, ki se niso odzvali na ostale zaviralce katehol-O-metiltransferaze (COMT), ali pa jih ne prenašajo (glejte poglavje 5.1).
Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy.
Zdravilo Tasmar ni priporočljivo za uporabo pri otrocih, starih do 18 let, ker so podatki o varnosti in učinkovitosti pomanjkljivi.
Tasmar is used to treat patients with Parkinson’s disease.
Zdravilo Tasmar se uporablja za zdravljenje bolnikov s Parkinsonovo boleznijo.
Tasmar is used together with other standard treatments for Parkinson’s disease (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patients have ‘fluctuations’ towards the end of the period between two doses of their standard combination.
Zdravilo Tasmar se uporablja skupaj z drugimi standardnimi zdravljenji Parkinsonove bolezni (bodisi s kombinacijo levodope in benserazida bodisi levodope in karbidope) pri bolnikih z „nihanji“ proti koncu obdobja med dvema odmerkoma običajne kombinacije zdravil.
Tasmar is used when all other alternative medicines cannot stabilise your Parkinson’s disease.
Zdravilo Tasmar uporabljamo, ko z drugimi zdravili ne moremo urediti vaše Parkinsonove bolezni.
Tasmar may be taken with or without food (see section 5.2).
Zdravilo Tasmar se lahko vzame s hrano ali brez nje (glej poglavje 5.2.)
Tasmar must also not be used in patients who are being treated with medicines known as non- selective monoamine oxidase (MAO) inhibitors.
Zdravila Tasmar prav tako ne smejo jemati bolniki, ki jemljejo zdravila, znana kot neselektivni zaviralci monoaminooksidaze (MAO).
Tasmar therapy should only be initiated by physicians experienced in the management of advanced Parkinson’s disease, to ensure an appropriate risk-benefit assessment.
Zdravljenje z zdravilom Tasmar naj uvedejo le zdravniki, izkušeni v zdravljenju napredovale Parkinsonove bolezni, da je zagotovljena primerna ocena razmerja med tveganjem in koristjo zdravljenja.
Tasmar treatment should also be discontinued if ALT (alanine amino transferase) and/or AST (aspartate amino transferase) exceed the upper limit of normal or symptoms or signs suggest the onset of hepatic failure (see section 4.4).
Zdravljenje z zdravilom Tasmar moramo prav tako prekiniti, če vrednosti ALT (alanin- aminotransferaza) in/ali AST (aspartat-aminotransferaza) presežejo zgornje referenčne vrednosti, ali če simptomi ali znaki kažejo na začetek okvare jeter (glejte poglavje 4.4)
Tasmar treatment should only be prescribed and supervised by a doctor who has experience in the management of advanced Parkinson’s disease.
Zdravljenje z zdravilom Tasmar mora predpisati in nadzorovati samo zdravnik z izkušnjami z zdravljenjem napredovale Parkinsonove bolezni.
Tasmar used with your other Parkinson medicines can cause excessive drowsiness (somnolence ) and sudden sleep onset episodes (you may suddenly fall asleep).
Zdravilo Tasmar lahko z uporabo ostalih vaših zdravil za zdravljenje Parkinsonove bolezni povzroči povečano zaspanost (somnolenco) in obdobja nenadnega uspavanja (nenadoma lahko zaspite).
taste abnormalities
motnje okušanja
Taste alteration (dysgeusia)
Sprememba okusa (disgevzija).
taste change
prememba okusa
taste changes
premembe okusa
Taste changes.
premembe okušanja
taste disorders
motnje okušanja
Taste disturbance
motnja okusa
Taste disturbance
motnja okušanja
taste disturbance
motnje okusa,
taste disturbance nausea (feeling sick)
prememba okusa navzea (siljenje na bruhanje)
taste disturbance or loss of taste
motnje čuta za okušanje ali izguba okusa,
taste disturbance,
motnje okušanja,
Taste disturbance3
motnje okušanja3
Taste disturbancej
motnje okušanjaj
Taste disturbances
motnje okusa,
Taste disturbances
motnje okušanja
taste disturbances
motnje okušanja,
taste disturbances sneezing
motnje okušanja kihanje
taste disturbances,
motnje okusa,
taste disturbances, feeling sick (nausea), mouth ulcers, being sick (vomiting), loss of appetite
motnje v okušanju, siljenje na bruhanje (navzea), razjede v ustih, bruhanje, izguba apetita
Taste disturbances, paraesthesia, headache, somnolence
motnje okušanja, parestezija, glavobol, somnolenca
Taste disturbances.
motnje okusa,
Taste disturbance§ Dizziness
motnje okušanja§ omotica
taste problems – such as changes in the way things taste
motnje okušanja – na primer spremenjen okus stvari
taste problems – such as changes in the way things taste
motnje okušanja – na primer spremenjen okus stvari,
tasvir
bitasvirjem
tasvir
Ctrough
tatins (e.g. rosuvastatin) anti-viral medicines (e.g. oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, lamivudine, zidovudine, zalcitabine)
tatine (npr. rosuvastatin) protivirusna zdravila (npr. oseltamivir, tenofovir, ganciklovir, adefovir, cidofovir, lamivudin, zidovudin, zalcitabin)
tatins (simvastatin and atorvastatin, both used to reduce the amount of cholesterol in blood).
tatine (simvastatin in atorvastatin za nižanje ravni holesterola v krvi).
tatins (simvastatin and atorvastatin, both used to reduce the amount of cholesterol in blood).
tatine (simvastatin in atorvastatin za nižanje ravni holesterola v krvi);
tatins (such as simvastatin, lovastatin, atorvastatin, rosuvastatin, or pravastatin) (for reducing the cholesterol in your blood);
tatini (kot so simvastatin, lovastatin, atorvastatin, rosuvastatin ali pravastatin) (za zniževanje ravni holesterola v vaši krvi),
tatins such as atorvastatin, fluvastatin, pitavastatin, lovastatin (used to lower blood cholesterol)
tatini, kot so atorvastatin, fluvastatin, pitavastatin in lovastatin (za zniževanje ravni holesterola v krvi)
tatins used to treat high cholesterol.
tatini, ki se uporabljajo za zdravljenje visoke ravni holesterola.
tatins – simvastatin or lovastatin
tatine – simvastatin ali lovastatin,
tatins, for example simvastatin, pravastatin – used to lower blood cholesterol levels
tatini, na primer simvastatin, pravastatin – uporabljajo se za zmanjševanje koncentracije holesterola v krvi,
Taupe
rjavosiva
TAUSSIG is an ongoing multicentre, open-label, 5-year extension study to assess the long-term safety and efficacy of Repatha, as an adjunct to other lipid lowering therapies, in patients with severe familial hypercholesterolaemia, including homozygous familial hypercholesterolaemia.
TAUSSIG je potekajoča multicentrična, odprta 5-letna podaljšana študija za oceno dolgoročne varnosti in učinkovitosti zdravila Repatha kot dodatka drugim zdravilom za zniževanje lipidov pri bolnikih s hudo družinsko hiperholesterolemijo, vključno s homozigotno družinsko hiperholesterolemijo.
Taxespira 120 mg/6 ml concentrate for solution for infusion Docetaxel
Taxespira 120 mg/6 ml koncentrat za raztopino za infundiranje docetaksel
Taxespira 140 mg/7 ml concentrate for solution for infusion Docetaxel
Taxespira 140 mg/7 ml koncentrat za raztopino za infundiranje docetaksel
Taxespira 160 mg/8 ml concentrate for solution for infusion Docetaxel
Taxespira 160 mg/8 ml koncentrat za raztopino za infundiranje docetaksel
Taxespira 20 mg/1 ml concentrate for solution for infusion Docetaxel
Taxespira 20 mg/1 ml koncentrat za raztopino za infundiranje docetaksel
Taxespira 80 mg/4 ml concentrate for solution for infusion Docetaxel
Taxespira 80 mg/4 ml koncentrat za raztopino za infundiranje docetaksel
Taxespira as single agent
Zdravilo Taxespirav monoterapiji
Taxespira can be used on its own after other treatments have failed.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Taxespira concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravila Taxespirakoncentrat za raztopino za infundiranje predhodno NI potrebno redčiti z vehiklom in je pripravljeno za dodajanje v infuzijsko raztopino.
Taxespira in combination with capecitabine
Zdravilo Taxespirav kombinaciji s kapecitabinom
Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Zdravilo Taxespirav kombinaciji s kapecitabinom je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke po neuspehu citotoksične kemoterapije.
Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Zdravilo Taxespiraje v kombinaciji s cisplatinom in 5-fluorouracilom indicirano za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu.
Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Zdravilo Taxespiraje v kombinaciji s cisplatinom in 5-fluorouracilom indicirano za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Zdravilo Taxespirav kombinaciji s cisplatinom je indicirano za zdravljenje neresektabilnega, lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka pri bolnikih, ki zaradi te bolezni še niso dobivali kemoterapije.
Taxespira in combination with doxorubicin
Zdravilo Taxespirav kombinaciji z doksorubicinom
Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Zdravilo Taxespiraje v kombinaciji z doksorubicinom in ciklofosfamidom indicirano za adjuvantno zdravljenje bolnic:
Taxespira in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Zdravilo Taxespirav kombinaciji z doksorubicinom in ciklofosfamidom: adjuvantno zdravljenje
Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Zdravilo Taxespirav kombinaciji z doksorubicinom je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, ki zaradi te bolezni še niso prejemale citotoksične terapije.
Taxespira in combination with platinum agents in chemotherapy-naïve patients
Zdravilo Taxespirav kombinaciji s platinskimi zdravili pri bolnikih, ki še niso bili zdravljeni s kemoterapijo
Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Zdravilo Taxespiraje v kombinaciji s prednizonom ali prednizolonom indicirano za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
Taxespira in combination with trastuzumab
Zdravilo Taxespirav kombinaciji s trastuzumabom
Taxespira in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Zdravilo Taxespiraje indicirano v kombinaciji s trastuzumabom za zdravljenje bolnic z metastatskim rakom dojke, katerih tumorji imajo čezmerno izražen HER2 in ki predhodno niso bile zdravljene s kemoterapijo za metastatsko bolezen.
Taxespira is a cancer medicine used to treat the following types of cancer:
z operabilnim rakom dojke s pozitivnimi bezgavkami z operabilnim rakom dojke z negativnimi bezgavkami.
Taxespira is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Taxespira solutions.
Zdravilo Taxespiraje antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem in pripravo raztopin zdravila Taxespirapotrebna previdnost.
Taxespira is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Zdravilo Taxespiraje indiciran za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Taxespira is used with prednisone or prednisolone (anti-inflammatory medicines); gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
255 bolnikih, ki so prejemali docetaksel v kombinaciji s kapecitabinom.
Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Zdravilo Taxespirav monoterapiji je indicirano za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, pri katerih predhodna citotoksična terapija ni bila uspešna.
Taxespira was administered as a 1-hour infusion, all other medicinal products were given intravenously on day 1 every three weeks.
Zdravilo Taxespiraje bilo uporabljeno v 1-urni infuziji, vsa druga zdravila pa intravensko 1. dan na tri tedne.
TAXOTERE 160 mg/8 ml concentrate for solution for infusion.
TAXOTERE 160 mg/8 ml koncentrat za raztopino za infundiranje
TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion docetaxel
TAXOTERE 20 mg/0,5 ml koncentrat in vehikel za raztopino za infundiranje docetaksel
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution containing 40 mg/ml docetaxel (anhydrous) in polysorbate 80 and citric acid.
Zdravilo TAXOTERE 20 mg/0,5 ml koncentrat za raztopino za infundiranje je bistra, viskozna, rumena do rjavorumena raztopina, ki vsebuje 40 mg brezvodnega docetaksela/ml v polisorbatu 80 in citronsko kislino.
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
Zdravilo TAXOTERE 20 mg/0,5 ml koncentrat za raztopino za infundiranje je bistra viskozna, rumena do rjavo-rumena raztopina.
TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion vial
Viala zdravila TAXOTERE 20 mg/0,5 ml koncentrat za raztopino za infundiranje:
TAXOTERE 20 mg/0.5 ml vial
Viala zdravila TAXOTERE 20 mg/0,5 ml:
TAXOTERE 20 mg/1 ml concentrate for solution for infusion
TAXOTERE 20 mg/1 ml koncentrat za raztopino za infundiranje
TAXOTERE 20 mg/1 ml concentrate for solution for infusion docetaxel
TAXOTERE 20 mg/1 ml koncentrat za raztopino za infundiranje docetaksel
TAXOTERE 20 mg/1 ml concentrate for solution for infusion docetaxel
TAXOTERE 20 mg/1ml koncentrat za raztopino za infundiranje docetaksel
TAXOTERE 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravilo TAXOTERE 20 mg/ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
TAXOTERE 80 mg/2 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution containing 40 mg/ml docetaxel (anhydrous) in polysorbate 80 and citric acid.
Zdravilo TAXOTERE 80 mg/2 ml koncentrat za raztopino za infundiranje je bistra, viskozna, rumena do rjavorumena raztopina, ki vsebuje 40 mg brezvodnega docetaksela/ml v polisorbatu 80 in citronsko kislino.
TAXOTERE 80 mg/2 ml concentrate for solution for infusion is a clear viscous, yellow to brown- yellow solution.
Zdravilo TAXOTERE 80 mg/2 ml koncentrat za raztopino za infundiranje je bistra viskozna, rumena do rjavo-rumena raztopina.
TAXOTERE 80 mg/2 ml concentrate for solution for infusion vial
Viala zdravila TAXOTERE 80 mg/2 ml koncentrat za raztopino za infundiranje:
TAXOTERE 80 mg/2 ml vial
Viala zdravila TAXOTERE 80 mg/2 ml:
TAXOTERE 80 mg/4 ml concentrate for solution for infusion
TAXOTERE 80 mg/ 4 ml koncentrat za raztopino za infundiranje
TAXOTERE 80 mg/4 ml concentrate for solution for infusion docetaxel
TAXOTERE 80 mg/4ml koncentrat za raztopino za infundiranje docetaksel
TAXOTERE 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Zdravilo TAXOTERE 80 mg/ 4ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
TAXOTERE as single agent
Zdravilo TAXOTERE v monoterapiji
TAXOTERE concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Zdravilo TAXOTERE koncentrat za raztopino za infundiranje je bledorumena do rjavo-rumena raztopina.
TAXOTERE concentrate SOLVENT for TAXOTERE
TAXOTERE koncentrat VEHIKEL za TAXOTERE
Taxotere docetaxel
Taxotere docetaksel
TAXOTERE has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer:
Zdravnik vam je zdravilo TAXOTERE predpisal za zdravljenje raka dojke, posebne vrste pljučnega raka (nedrobnocelični pljučni rak), raka prostate, raka želodca ali raka glave in vratu:
Taxotere has been studied in over 4,000 breast-cancer patients, around 2,000 non-small-cell-lung- cancer patients, 1,006 prostate-cancer patients, 457 gastric-adenocarcinoma patients and 897 head- and neck-cancer patients.
Zdravilo Taxotere so proučevali pri več kot 4 000 bolnicah z rakom dojke, približno 2 000 bolnikih z nedrobnoceličnim pljučnim rakom, 1 006 bolnikih z rakom prostate, 457 bolnikih z želodčnim adenokarcinomom in 897 bolnikih z rakom glave in vratu.
TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Zdravilo TAXOTERE je v kombinaciji z doksorubicinom in ciklofosfamidom indiciran za adjuvantno zdravljenje bolnic:
TAXOTERE in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Zdravilo TAXOTERE v kombinaciji z doksorubicinom in ciklofosfamidom: adjuvantno zdravljenje
TAXOTERE in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Zdravilo TAXOTERE je v kombinaciji s prednizonom ali prednizolonom indiciran za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
Taxotere is a medicine that contains the active substance docetaxel.
Taxotere je zdravilo, ki vsebuje zdravilno učinkovino docetaksel.
TAXOTERE is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing TAXOTERE solutions.
TAXOTERE je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem in pripravo raztopin zdravila TAXOTERE potrebna previdnost.
TAXOTERE is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing TAXOTERE solutions.
Zdravilo TAXOTERE je antineoplastično zdravilo in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem in pripravo raztopin zdravila TAXOTERE potrebna previdnost.
Taxotere is given as a one-hour infusion every three weeks.
Zdravilo Taxotere se daje v obliki enourne infuzije vsake tri tedne.
Taxotere is used to treat the following types of cancer:
Zdravilo Taxotere se uporablja za zdravljenje naslednjih vrst raka:
Taxotere is used with cisplatin and 5-fluorouracil (other anticancer medicines); head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Zdravilo Taxotere se uporablja s cisplatinom in 5-fluoroacilom (drugima zdraviloma proti raku); lokalno napredovalem raku glave in vratu pri bolnikih (rak je zrastel, vendar se ni razširil).
Taxotere is used with cisplatin and 5-fluorouracil.
Zdravilo Taxotere se uporablja s cisplatinom in 5-fluoroacilom.
Taxotere is used with prednisone or prednisolone (anti-inflammatory medicines);
Zdravilo Taxotere se uporablja s prednizonom ali prednizolonom (protivnetnima zdraviloma);
Taxotere must not be used in people who are hypersensitive (allergic) to docetaxel or any of the other ingredients.
Zdravila Taxotere ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) docetaksel ali katero koli drugo sestavino zdravila.
Taxotere should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Zdravilo Taxotere je treba uporabljati na specializiranih oddelkih za kemoterapijo (kjer se uporabljajo zdravila proti raku) in se sme dajati le pod nadzorom zdravnika, usposobljenega za uporabo kemoterapije.
TAXOTERE should not be used after the expiry date shown on the carton, blister pack and vials.
Zdravila TAXOTERE 80 mg ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, pretisnem omotu in vialah.